JCSG.org supplies the Body Pharm BPC-157 & TB500 32 Pen with South African delivery. This guide covers the device specifications, dosing protocol, and stack context.
Key Takeaways
- The Body Pharm BPC-157 & TB500 32 Pen delivers 16 mg BPC-157 plus 16 mg TB-500 across 32 selectable doses (0.25–1 mg per click), with no reconstitution required.
- Subcutaneous injection protocol uses a 45° angle into the abdomen, thigh, or lower back, rotating sites every dose to prevent lipodystrophy.
- A single pen supports a 4-week once-daily cycle or a 2-week twice-daily cycle; community protocols recommend a 4-week washout between cycles.
- Both peptides remain preclinical (no Phase I or II human musculoskeletal trials published as of 2026); all claimed benefits are extrapolated from rodent and cell-culture work.
- Neither compound is SAHPRA-approved; both are sold as unregistered, unscheduled research chemicals for laboratory use only.
What Is the Body Pharm BPC-157 & TB500 32 Pen?
The Body Pharm BPC-157 & TB500 32 Pen is a pre-filled, multi-dose subcutaneous injector containing 16 mg BPC-157 plus 16 mg TB-500 (32 mg total peptide blend) across 32 selectable doses. Body Pharm manufactures it and JCSG.org supplies it in South Africa. The pre-filled format removes reconstitution variance, which matters for researchers who need consistent dose delivery across multiple injections.
Specifications at a glance:
- Total content: 32 mg blend (16 mg BPC-157 + 16 mg TB-500) per pen.
- Doses per pen: 32, with dial settings of 0.25, 0.5, 0.75 or 1 mg total blend per click.
- Format: pre-loaded liquid pen — no reconstitution with bacteriostatic water required.
- Manufacturer: Body Pharm.
- Current SA price: shown in the buy box at the top of this page.
The per-click split between the two peptides is inferred from the stated 1:1 ratio (approximately 125–500 mcg of each peptide per click at the 0.25–1 mg settings) rather than printed on web-accessible labelling. Confirm the breakdown against the physical box or insert before dosing.
For mechanistic background on the individual compounds, see the BPC-157 peptide profile and the TB500 peptide profile. Both remain preclinical/research-grade in 2026, with no Phase I or II musculoskeletal trials published for either compound [8].
BPC-157 and TB-500: Mechanisms at a Glance
BPC-157 and TB-500 are combined because they target tissue repair through complementary pathways. BPC-157 drives local angiogenic and fibroblast activity at the injury site, while TB-500 supports systemic cell migration and vascular remodelling. All mechanistic claims below come from preclinical (animal and in vitro) work; no completed human Phase I or II musculoskeletal RCTs for either compound had been published by 2026 [5][8].
-
BPC-157 is a synthetic pentadecapeptide derived from a protective sequence in human gastric juice. Proposed actions include upregulation of growth-hormone-receptor expression on tendon fibroblasts, modulation of the nitric oxide (NO) system, and promotion of fibroblast migration and tendon outgrowth in rat models (Sikiric et al., 2018) [5]. This local activity makes it suited to subcutaneous depot injection near an injury site.
-
TB-500 is a synthetic fragment corresponding to amino acids 17–23 of the 43-amino-acid Thymosin Beta-4 protein. Its central mechanism is actin sequestration, which enables cell migration, angiogenesis, and recruitment of progenitor cells to damaged tissue. The small molecular weight (approximately 494 Da) allows rapid systemic distribution.
-
BPC-157's activity is predominantly local when injected subcutaneously near or distal to an injury. Rodent data suggests effects on tendon-to-bone healing and gastrointestinal mucosal repair [5]. This localisation occurs because the peptide is larger (1,420 Da) and less water-soluble than TB-500.
-
TB-500's activity is predominantly systemic because the fragment is small, water-soluble, and circulates readily. Preclinical work shows TB-500 reaching distant tissues within hours of injection, which is why combination protocols rely on it for whole-body regenerative signalling rather than site-specific action.
-
The combination rationale is additive coverage. Pairing a locally acting cytoprotective peptide (BPC-157) with a systemically distributing migration/angiogenesis signal (TB-500) means a single subcutaneous click addresses both the wound bed and the circulatory contribution to repair [5]. That dual coverage is why the 1:1 ratio is maintained in the Body Pharm formulation.
The BPC-157 peptide profile covers the Sikiric mechanistic literature in more depth, and the TB500 peptide profile details the Thymosin Beta-4 parent-molecule data, including the older ophthalmic and cardiac human trials that do not translate to musculoskeletal endpoints.
Synergistic Stack Benefits: What the Research Suggests
The proposed benefits of combining BPC-157 and TB-500 cluster around four mechanisms documented in rodent and cell-culture work. None has been replicated in human randomised controlled trials as of 2026 [5]. Treat each benefit below as a hypothesis carried over from preclinical models, not a clinical endpoint.
Accelerated wound and soft-tissue healing
BPC-157 promotes fibroblast migration and tendon outgrowth in rat Achilles transection models. TB-500 sequesters G-actin to enable the cytoskeletal reorganisation that any migrating cell requires (Sikiric et al., 2018) [5]. The combination rationale is that BPC-157 supplies the local cytoprotective signal at the wound bed while TB-500 supplies the intracellular machinery for cell movement. Preclinical evidence only — not replicated in human RCTs as of 2026 [5].
Joint and tendon support
BPC-157 has been shown to upregulate collagen type I gene expression in cultured tendon fibroblasts and to modulate the nitric oxide system in rat tendon-to-bone healing assays [5]. TB-500's parent molecule, Thymosin Beta-4, downregulates inflammatory cytokines in animal injury models, which is the basis for the anti-inflammatory framing in stack protocols. The pairing is plausible mechanistically, but no orthopaedic Phase I or II trial of either compound has been published in 2024–2026 [5]. Preclinical and parent-molecule evidence only.
Muscle recovery
TB-500 is cited for satellite cell activation and myoblast migration in rodent skeletal-muscle injury models. BPC-157 is separately reported to reduce oxidative stress markers (malondialdehyde, lipid peroxidation) in rat crush-injury studies through 2024 [5]. The BPC-157 peptide profile and TB500 peptide profile collate the underlying rodent citations. Preclinical evidence only — not replicated in human RCTs as of 2026 [5].
Angiogenesis and nutrient delivery
Both peptides are reported to upregulate vascular endothelial growth factor (VEGF) expression in animal models: BPC-157 in gastric and tendon tissue, TB-500 systemically via endothelial cell migration [5]. The functional claim is that improved capillary density at the repair site supports oxygen and nutrient delivery during the proliferative phase of healing. This is the most consistent overlapping mechanism between the two peptides in preclinical literature. Preclinical evidence only — not replicated in human RCTs as of 2026 [5].
Per-Dose Composition of the 32 mg Pen
Each click on the Body Pharm 32 Pen delivers 1 mg of total blended peptide, with the pen housing 32 mg across 32 doses at the maximum setting. The 16 mg BPC-157 + 16 mg TB-500 total fill mathematically implies a 0.5 mg + 0.5 mg per-click split at the 1 mg setting. The per-peptide breakdown should be confirmed against the physical packaging before research use.
The selectable dose dial offers 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg settings, all referring to total blend rather than per-peptide quantity.
Inferred per-dose breakdown (1:1 blend assumption)
| Pen total | Doses | Dial setting | BPC-157 per dose | TB-500 per dose |
|---|---|---|---|---|
| 32 mg (16 + 16) | 32 at 1 mg | 0.25 mg | ~125 mcg [unverified] | ~125 mcg [unverified] |
| 32 mg (16 + 16) | 32 at 1 mg | 0.5 mg | ~250 mcg [unverified] | ~250 mcg [unverified] |
| 32 mg (16 + 16) | 32 at 1 mg | 0.75 mg | ~375 mcg [unverified] | ~375 mcg [unverified] |
| 32 mg (16 + 16) | 32 at 1 mg | 1 mg | ~500 mcg [unverified] | ~500 mcg [unverified] |
Verification note: the per-peptide mcg figures above are arithmetic inferences from the stated 16 mg + 16 mg total content. No Body Pharm certificate of analysis or label photograph confirming the exact split has been located on distributor pages as of 2026. Request a batch-specific CoA from your JCSG.org order before relying on these figures for any documented protocol.
Why a fixed ratio matters
A pre-blended 1:1 cartridge removes the reconstitution variance that arises when pairing separate vials. Bacteriostatic water volume, syringe dead space, and draw accuracy each introduce error. For the individual-vial dosing maths that the pen abstracts away, see the BPC-157 peptide profile and the TB500 peptide profile.
Step-by-Step Subcutaneous Injection Protocol
Administer the Body Pharm pen subcutaneously into the abdomen, outer thigh, or lower back at a 45° angle, using the dialled dose and rotating sites each session. The sequence below is written specifically for the pre-filled cartridge format and assumes the dose has already been set on the dial.
-
Temper the pen. Remove it from refrigeration 10–15 minutes before injection so the solution reaches room temperature. This reduces sting and improves plunger glide. Do not warm with hot water or direct sunlight.
-
Attach a fresh pen needle and prime according to the manufacturer's pen-needle instructions. Discard any initial air-bead the dial recommends clearing.
-
Confirm the dose on the dial (0.25 mg, 0.5 mg, 0.75 mg, or 1 mg of total blend). Re-check the window before each click to avoid stacking doses.
-
Clean the injection site with a 70% isopropyl alcohol swab in a single outward spiral, then allow the skin to air-dry fully. Injecting through wet alcohol increases sting.
-
Pinch a fold of skin between thumb and forefinger at the chosen site. For the abdomen, stay at least 5 cm clear of the navel on either side; the outer thigh and lower-back flank are equally valid subcutaneous depots.
-
Insert the needle at a 45° angle into the subcutaneous fat layer beneath the pinch. A 45° angle is the standard subcutaneous technique for short pen needles in lean research subjects; users with more adipose tissue can use 90° with a 4–6 mm needle.
-
Depress the plunger slowly and steadily until the dial returns to zero. Hold for a 5–10 second count before withdrawing to allow the full bolus to deposit.
-
Withdraw the needle at the same angle, then apply light pressure with a dry swab. Do not rub the site, as this can disperse the depot and promote bruising.
-
Recap, log the site, and refrigerate the pen at 2–8°C between uses. Record which quadrant was used so the next injection rotates to an unused site.
Site rotation map
Rotate across at least four sites in a fixed sequence: left abdomen, right abdomen, left outer thigh, right outer thigh, with the lower-back flank as a fifth option. Repeated injection into the same square centimetre risks lipodystrophy and inconsistent absorption, which would confound any recovery observations being recorded. The BPC-157 peptide profile and TB500 peptide profile cover the individual pharmacokinetics that justify this rotation pattern.
For research use only. BPC-157 and TB-500 remain unregistered, unscheduled experimental peptides in South Africa as of 2026 [6].
Recommended Cycle Length and Injection Frequency
A 32-dose pen supports roughly four weeks at one injection per day, or two weeks at two injections per day, after which community protocols suggest a four-week washout before any subsequent cycle. No peer-reviewed human trial has established a standardised dosing schedule for either peptide in musculoskeletal recovery, so every figure below is community consensus and manufacturer suggestion, not clinical guidance [5].
The most commonly referenced research framework runs as follows:
-
Select frequency by objective. Once-daily dosing is the default for general soft-tissue research protocols; twice-daily dosing appears in forum protocols targeting acute injury models, front-loading the first 7–14 days [unverified].
-
Set cycle length at 4–8 weeks. Community protocols cluster around 28–56 continuous days of dosing, with the shorter end paired with twice-daily injections and the longer end with once-daily [unverified].
-
Calculate pen supply. 32 doses ÷ 1 per day = a 32-day supply, covering one full four-week cycle from a single pen. 32 doses ÷ 2 per day = a 16-day supply, meaning a twice-daily 4-week cycle requires two pens and an 8-week twice-daily cycle requires four.
-
Observe a 4-week off period. Forum consensus recommends a minimum 28-day washout between cycles to reassess baseline before any repeat administration [unverified].
-
Log outcomes against the washout. Recovery markers recorded during the off period are what justify, or rule out, a subsequent cycle.
None of the above is endorsed by SAHPRA or supported by 2024–2026 Phase I/II data [5]. For the individual pharmacology underpinning these intervals, see the BPC-157 peptide profile and TB500 peptide profile.
Pen Format vs. Separate Vials: A Direct Comparison
The pen wins on convenience and dose consistency; separate vials win on ratio flexibility and bulk economics. Which matters more depends on whether the research protocol requires a fixed 1:1 BPC-157:TB-500 ratio (pen) or independent titration of each peptide (vials).
| Criterion | Body Pharm 32-dose Pen | Separate Lyophilised Vials |
|---|---|---|
| Reconstitution required | No, pre-filled and pre-mixed | Yes, bacteriostatic water plus insulin syringe per vial |
| Dose consistency | Fixed click increments of 0.25, 0.5, 0.75 or 1 mg total blend | Operator-dependent; volumetric measurement error per draw |
| Portability | Single pen, refrigerated transport only | Two vials, diluent, syringes, alcohol swabs |
| Cost per dose | Shown in the buy box | Varies by format |
| Flexibility to adjust ratio | None, locked at 1:1 (16 mg BPC-157 + 16 mg TB-500) | Full independent control of each peptide's dose |
| Shelf life once opened | Confirm against physical insert | Reconstituted vial typically refrigerated, manufacturer-dependent |
Reconstitution error is the primary variable when comparing the pen against standard lyophilised vials. A 10 mg vial reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL; drawing 0.05 mL on an insulin syringe to hit a 250 mcg dose introduces meaningful error at the 2-unit graduation. The pen removes that variable entirely at the cost of locking the ratio. For protocols where the research question is the combined effect, that trade favours the pen. For protocols isolating BPC-157 or TB-500 alone, separate vials are the only sensible format. See the BPC-157 peptide profile and TB500 peptide profile for standalone use cases.
A Note on Oral Capsules
A third format exists locally as oral BPC-157 capsules. Oral bioavailability of BPC-157 in humans has not been quantified in any 2024–2026 trial [8][unverified], and no oral TB-500 product is in circulation. Capsules are not a substitute for the injectable pen in any protocol described in this guide.
Storage Conditions and Shelf Life
Store the Body Pharm BPC-157 & TB500 pen refrigerated at 2–8°C, protected from light, and away from heat sources. Do not freeze the pen — ice crystal formation degrades peptide structure and the cartridge cannot be re-homogenised once damaged.
Follow this order of operations from delivery onward:
-
On arrival, transfer the pen directly to the fridge (2–8°C). Brief courier transit at ambient temperature is generally tolerated for lyophilised and stabilised peptide formats, but the pen should not sit on a kitchen counter overnight.
-
Before first use, confirm the unopened expiry printed on the pen body or carton. Body Pharm does not publish a generic shelf-life figure on all listings, so the printed date on the unit is the only authoritative source.
-
After first dose (needle attached, seal broken), treat the pen as an opened multi-dose injectable. The opened use-by period is not stated on all Body Pharm listings [unverified]; 28–30 days is a typical industry default for opened peptide pens, but confirm against the physical insert before relying on it.
-
During load-shedding, keep a small insulated cool bag with two frozen gel packs in the freezer compartment as a contingency. Eskom Stage 4–6 schedules can produce 4+ hour outages back-to-back; transferring the pen to the cool bag keeps it inside the 2–8°C window without the gel packs touching the cartridge directly (direct contact risks localised freezing).
-
Never re-use a pen that has been left at room temperature for more than a few hours, or that shows cloudiness or particulate matter in the cartridge window.
For mechanism-level background on each compound's stability profile, see the BPC-157 peptide profile and TB500 peptide profile.
Known Side Effects and Safety Considerations
Human safety data for the BPC-157 and TB-500 combination remains limited as of 2026. Every safety statement below is extrapolated from preclinical work or anecdotal user reports rather than controlled clinical trials [5]. No Phase I or II randomised trial of either commercial peptide for musculoskeletal indications has been published in the 2024–2026 window [5], so long-term human safety is genuinely unknown.
Side effects most frequently reported by community users of the Body Pharm pen fall into three categories:
- Injection-site reactions — localised redness, mild swelling, or a small bruise at the subcutaneous site. Anecdotally the most common complaint and usually resolves within 24–48 hours. Rotate sites as set out earlier to limit recurrence.
- Transient nausea — described with BPC-157, more often at the upper end of the 0.25–1 mg dial settings. Preclinical rodent work has not flagged a clear emetic mechanism, so this remains anecdotal and unverified [5].
- Dizziness or light-headedness — reported by some users after TB-500 dosing, particularly during the first few injections of a cycle. No controlled human data confirms a causal link [5].
Pro-angiogenic caution and oncology history
TB-500's mechanism involves promoting angiogenesis and cell migration — the same property that underpins its hypothesised tissue-repair effect. In preclinical models this raises a theoretical concern about accelerating growth of existing, undiagnosed tumours. The concern is mechanistic and has not been confirmed as a clinical risk in humans [5]. Anyone with a personal or family history of malignancy should not self-administer this pen without oncology input.
Consult a registered medical practitioner — ideally one familiar with experimental peptides — before starting a cycle. The BPC-157 peptide profile and TB500 peptide profile cover the underlying pharmacology in more depth.
Regulatory Status in South Africa (2026)
Neither BPC-157 nor TB-500 has received SAHPRA approval for human therapeutic use in South Africa as of 2026. Both compounds are absent from SAHPRA's published Schedules to the Medicines and Related Substances Act and from the searchable medicine register, making them unregistered, unscheduled experimental peptides rather than scheduled medicines. Verify this status directly at sahpra.org.za at the time of purchase, because schedules can be updated without a long lead time and enforcement posture has shifted across 2024–2026.
The Body Pharm pen is sold as a research chemical for laboratory use only.
How this compares internationally
The US FDA has not approved BPC-157 or TB-500 for any human indication, and both sit outside the FDA's bulk-compounding Category 1 list as of 2026. The EMA has likewise not authorised either peptide for human therapeutic use. No 2024–2026 Phase I or II musculoskeletal trial for either compound has been published, so the preclinical-only status used throughout this guide still holds [5].
For mechanism-level background on each compound individually, see the BPC-157 peptide profile and TB500 peptide profile.
Frequently Asked Questions
How many doses does the Body Pharm BPC-157 & TB500 pen contain?
The Body Pharm pen contains 32 doses at the 1 mg total-blend setting, drawn from 16 mg BPC-157 plus 16 mg TB-500 in a 1:1 ratio. At the 0.5 mg setting it yields 64 doses, and at the 0.25 mg setting roughly 128 doses, though dose accuracy at lower clicks depends on pen calibration.
Can I use the pen without reconstituting anything?
Yes. The Body Pharm 32-dose pen is sold pre-filled and pre-mixed, so no bacteriostatic water, mixing vial, or separate syringe is required before the first click. This is the main practical difference versus lyophilised vial formats, which need reconstitution and careful volumetric measurement for every dose.
What is the difference between BPC-157 and TB-500 in this blend?
BPC-157 is a 15-amino-acid synthetic pentadecapeptide studied preclinically for gastrointestinal and tendon-ligament repair, while TB-500 is a synthetic fragment of Thymosin Beta-4 investigated for actin regulation, angiogenesis, and soft-tissue migration [5]. The Body Pharm pen combines them at 16 mg each. See the BPC-157 peptide profile and TB500 peptide profile.
How long does one pen last?
One pen lasts 32 days at the standard once-daily 1 mg total-blend protocol. Researchers running split AM/PM dosing at 0.5 mg per click extend the same pen to roughly 32 days of twice-daily use (64 clicks), while a conservative 0.25 mg single daily dose stretches one pen across approximately four months.
Where can I buy the Body Pharm BPC-157 & TB500 pen in South Africa?
JCSG.org supplies Body Pharm research peptides in South Africa. The current price and stock availability are shown in the buy box at the top of this page.
Is BPC-157 and TB-500 approved by SAHPRA?
No. Neither BPC-157 nor TB-500 appears in SAHPRA's published Schedules to the Medicines and Related Substances Act or its registered-medicines database as of 2026, making them unregistered, unscheduled experimental peptides sold strictly for laboratory research use. Verify status at sahpra.org.za before purchase.
Related Peptides Worth Exploring
Three peptides commonly sit alongside the Body Pharm BPC-157 & TB500 pen in South African research stacks, each addressing a different mechanism:
-
GHK-Cu — a copper tripeptide studied preclinically for collagen synthesis, wound remodelling, and skin repair. Researchers running tendon or post-surgical protocols sometimes pair it with the BPC-157/TB-500 blend for its complementary extracellular matrix activity.
-
Body Pharm CJC-1295 & Ipamorelin 20 Pen — a growth-hormone-releasing hormone (GHRH) analogue plus ghrelin mimetic combination targeting the growth hormone axis. The pen format mirrors the BPC/TB-500 device, making parallel dosing logs straightforward.
-
Body Pharm MOTS-C 32 Pen — a mitochondrial-derived peptide investigated for metabolic regulation and insulin sensitivity, used by researchers studying recovery alongside soft-tissue repair.
For mechanistic depth on the individual components of this stack, see the BPC-157 peptide profile and TB500 peptide profile.
Ordering and Pre-Cycle Checklist
JCSG.org ships the Body Pharm BPC-157 & TB500 32 Pen across South Africa. The current price is shown in the buy box at the top of this page.
Before starting a cycle, confirm the current regulatory status at sahpra.org.za, request a batch-specific certificate of analysis with your order to verify the per-peptide dose split, and consult a registered medical practitioner familiar with experimental peptides. Once you have verified the product and obtained professional input, set up a dosing log to track injection sites, dates, and any observed changes in recovery markers or side effects across your 4–8 week cycle and subsequent washout period.
